Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 16:2022:5096825.
doi: 10.1155/2022/5096825. eCollection 2022.

Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity

Muluken Altaye Ayza  1 , Kaleab Alemayehu Zewdie  2 , Elias Fitsum Yigzaw  3 , Solomon Gashaw Ayele  4 , Bekalu Amare Tesfaye  2 , Gebrehiwot Gebremedhin Tafere  2 , Muzey Gebreyohannes Abrha  5
Affiliations
Review

Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity

Muluken Altaye Ayza et al. Int J Nephrol. .

Abstract

Cyclophosphamide is an alkylating antineoplastic agent, and it is one of the most successful drugs with wide arrays of clinical activity. It has been in use for several types of cancer treatments and as an immunosuppressive agent for the management of autoimmune and immune-mediated diseases. Nowadays, its clinical use is limited due to various toxicities, including nephrotoxicity. Even though the mechanisms are not well understood, cyclophosphamide-induced nephrotoxicity is reported to be mediated through oxidative stress. This review focuses on the potential role of natural and plant-derived antioxidants in preventing cyclophosphamide-induced nephrotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Major metabolism and disposition pathways of cyclophosphamide.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Al-Homsi A. S., Roy T. S., Cole K., Feng Y., Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biology of Blood and Marrow Transplantation . 2015;21(4):604–611. doi: 10.1016/j.bbmt.2014.08.014. - DOI - PubMed
    1. Arnold H., Bourseaux F., Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat. Nature . 1958;181(4613):p. 931. doi: 10.1038/181931a0. - DOI - PubMed
    1. Brass S. D., Weiner H. L., Hafler D. A. Multiple sclerosis. In: Rose N. R., Mackay I. R., editors. Autoimmune Diseases . 4th. St. Louis, MO, USA: Academic Press; 2006. pp. 615–632. - DOI
    1. Kim J., Chan J. J. Cyclophosphamide in dermatology. Australasian Journal of Dermatology . 2017;58(1):5–17. doi: 10.1111/ajd.12406. - DOI - PubMed
    1. De Jonge M. E., Huitema A. D. R., Rodenhuis S., Beijnen J. H. Clinical pharmacokinetics of cyclophosphamide. Clinical Pharmacokinetics . 2005;44(11):1135–1164. doi: 10.2165/00003088-200544110-00003. - DOI - PubMed

LinkOut - more resources